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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
aerobic and resistance exercise reduces fatigue in men with prostate cancer. 
 
STUDY DESIGN: Systematic review of three randomized controlled trials (RCT’s) published 
in peer reviewed journals between 2013-2017.  
 
DATA SOURCES: Data sources obtained for this review were found in using PubMed and 
Cochrane Library and chosen based on their relevance to the clinical question and if they 
included patient oriented evidence that matters (POEMS)  
 
OUTCOMES MEASURED: All three studies measured the effect aerobic and resistance 
exercise has on fatigue in men with prostate cancer undergoing androgen deprivation therapy 
and/or radiation therapy using self-reporting questionnaires.  
 
RESULTS: All three studies contained continuous data that could not be converted to 
dichotomous date. P values were reported for each of the studies. The p values for every trial 
reported a p value of <.05 thus concluding the data to be statistically significant. Each of the 
studies selected found with statistical significance that aerobic and resistance exercise reduced 
the level of fatigue reported by the participants of the trial.  
 
CONCLUSIONS: After analysis of the three trials, exercise can lead to a reduction in fatigue in 
men diagnosed with prostate cancer undergoing androgen deprivation therapy (ADT) and/or 
radiation therapy (RT). Exercise is a cost-effective option for patients and can have beneficial 
effects over other medical conditions. The populations studied in this review focused on men 
receiving ADT and/or RT. Future studies can focus on other treatment modalities such as 
chemotherapy. Further research can also include larger sample sizes and longer trials to 
effectively evaluate the long-term effects of exercise and fatigue.  
 
KEYWORDS: Prostate cancer, exercise programs, and fatigue 
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INTRODUCTION 
Prostate cancer is one of the most common types of cancer in American men and is the 
second leading cause of death for men in the US.1 Prostate cancer is a slow growing cancer that 
originates in the prostate and is often asymptomatic especially in the early stages. If symptoms 
do arise they can mimic other conditions of the prostate such as benign prostatic hypertrophy. 
Common symptoms include problems urinating, slow or weak urinary stream, inability to 
urinate, discomfort in the pelvic area, and blood in semen. The exact cause of prostate cancer is 
unknown but increasing age and being of African American decent are two identified risk 
factors.1 Prostate cancer is rare in men younger then 40 and the prevalence of prostate cancer is 
highest in men 65 years or older.1 
One in nine men are diagnosed with prostate cancer in their lifetime and this causes a 
large financial burden on the healthcare system.1 In 2018 the United States had an estimated 
164,690 new cases of prostate cancer reported.1 “In the USA, the total estimated expenditure on 
prostate cancer was 9.862 billion US dollars ($) in 2006. The mean annual costs per patient in 
the USA were $10,612 in the initial phase after diagnosis, $2134 for continuing care and $33,691 
in the last year of life.”2 Once diagnosed, follow up care is essential in maintaining good health 
and managing side effects of treatment. Prostate cancer treatments come with a wide array of 
side effects. One adverse effect which significantly effects quality of life is fatigue. “40% or 
more of those on long term ADT reporting chronic fatigue or clinically-relevant fatigue which 
interferes with daily functioning.”3 Physician assistants have the opportunity to manage prostate 
cancer patients and the side effects from the treatments they receive.   
 Once diagnosed, the treatment modality depends on the stage and progression of the 
disease. Early stage prostate cancer typically grows very slowly and often remains 
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asymptomatic. Often treating the cancer would cause more problems than no treatment. 
Therefore, watchful waiting and active surveillance is often chosen as the treatment modality in 
these patients. Active surveillance includes monitoring PSA levels, performing digital rectal 
exams and prostate biopsies to monitor the stage of the cancer.4 The cancer is monitored closely 
for signs of progression that would require further treatment. More advanced stages of prostate 
cancer can undergo radiation, chemotherapy, androgen deprivation therapy, and surgery. Radical 
prostatectomy can be used in more localized disease and involves surgically removing the 
prostate, seminal vesicles and ampulla of the vas deferens.4 Radiation can also be used in 
localized disease in attempt to kill the cancerous cells.4 More systemic treatment modalities can 
be used when the cancer is not localized to a specific area of the body. “The mainstay of 
treatment of more advanced prostate cancer is androgen-deprivation therapy (ADT).”5 Male sex 
hormones such as testosterone help prostate cancer cells grow and causes further progression of 
the cancer.6 Androgen deprivation therapy causes lowering of these male sex hormones and can 
be an effective treatment modality.6 Androgen deprivation therapy can be achieved by surgical 
orchiectomy or drugs like luteinizing hormone-releasing hormone (LHRH) agonists.6 Surgical 
orchiectomy, also called surgical castration, is a procedure that removes one or both testicles that 
ultimately reduce the levels of testosterone in the body.6 Drugs such as LHRH agonists, also 
called medical castration, can be used to lower male sex hormone levels in the body.6 
Chemotherapy is another treatment modality that is utilized in more systemic disease.4 
 The treatment options listed above are associated with side effects. The three RCTs that 
are evaluated in this systematic review focus on men receiving androgen deprivation therapy and 
radiation treatment. Many side effects are reported by patients receiving these two treatment 
modalities but one in particular is fatigue. The fatigue experienced by these patients has a great 
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impact on the individual’s quality of life. Patients often feel drained and are unable to carry out 
their activities of daily living. Physical activity has been shown to improve cardiovascular health 
and reduce fatigue.3 Therefore, it is proposed that exercise programs may help improve fatigue 
experienced by men undergoing prostate cancer treatment. This paper evaluates three 
randomized controlled trials (RCTs) comparing the efficacy of resistance and aerobic exercise 
programs on fatigue in men with prostate cancer receiving androgen deprivation therapy and/or 
radiation therapy. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not aerobic and 
resistance exercise reduces fatigue in men with prostate cancer.  
METHODS 
 Three RCTs that included men diagnosed with prostate cancer undergoing androgen 
deprivation therapy and/or radiation therapy were selected for analysis. All studies used aerobic 
and resistance exercises as the experimental intervention and compared the results to participants 
undergoing usual daily activity or delayed exercise. The Taaffe et al. study compared 2 
experimental groups and 1 control group.3 The 2 experimental groups participated in either 
impact loading and resistance training (ILRT) or aerobic and resistance training (ART).3 The 
ILRT group participated in a twice weekly exercise program at a clinic and twice weekly home 
exercise program for 12 months.3 The ART group participated in supervised exercise in the 
clinic 2 times a week and home aerobic activity for 6 months followed by a home exercise 
program for the next 6 months.3 The delayed or usual care group (DEL) served as the studies 
control.3 The DEL group was instructed to perform delayed exercise for 6 months with an 
instruction booklet followed by a 6-month twice weekly stationary cycling exercise.3  
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The Hojan et al. study focused on a 12-month physical exercise program in men with 
prostate cancer undergoing ADT and RT.7 The physical exercise program consisted of 5 exercise 
sessions a week for 8 weeks during RT and then followed by 3 days a week for the next 10 
months.7 The physical activity consisted of aerobic and resistance exercises.7 Participants in the 
control group were instructed not to start any formal physical activity, but continue to perform 
usual daily activity at home.7  
The Bourke et al. study focused on a 12-week aerobic and resistance exercise program on 
men receiving ADT.5 The exercise program started with supervised aerobic and resistance 
exercises that occurred twice a week for the first 6 weeks and once a week for the remaining 6 
weeks.5 The men were also instructed to perform a self-directed exercise session once a week for 
the first 6 weeks and then twice a week for the remaining 6 weeks.5 A dietary plan was also 
given to the participants in the experimental group.5 Men in the control group were instructed to 
perform usual care and no restrictions were placed on their activity.5 The outcome ultimately 
measured in the 3 studies was to evaluate the effect aerobic and resistance exercise has on fatigue 
in men undergoing ADT and/or RT.  
 All of the articles chosen for this systematic review were published in English in peer 
review journals and found in the following databases: PubMed, Cochrane Library. The keywords 
“prostate cancer”, “exercise programs”, and “fatigue” were used to find the articles and then 
selected based on their relevance to each other, my clinical question and the presence of patient 
oriented evidence that matters (POEMs). Articles were excluded if a systematic review was 
present on the clinical topic with the caveat that three RCT’s were published after the systematic 
review. Inclusion criteria for the selected articles required the use of RCT’s and studies 
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published in the past 10 years. The statistics reported in the articles include p-value and f-score. 
The demographics and characteristics of the included studies are presented in table 1.  
Table 1. Demographics of included studies  
Study 
 
Type #Pts Age(yrs) Inclusion Criteria Exclusion Criteria W/D Interventions 
Taaffe et 
al.3 
(2017) 
 
RCT 163 43-
90yrs 
-Men with documented 
prostate cancer and a 
minimum 2 month 
exposure to androgen 
deprivation therapy 
-Did not contain prostate 
specific antigen evidence 
of disease activity  
-Anticipated to receive 
androgen deprivation 
therapy for the next 12 
months 
-Bone metastatic disease, 
musculoskeletal, 
cardiovascular, or 
neurological conditions 
that could inhibit them 
from exercising 
-Lack the ability to walk 
400 meters or perform 
exercise  
-Did not receive 
structured resistance and 
aerobic training in the 
previous 3 months  
   
 
7 -Exercise 
program:  
Supervised 
aerobic and 
resistance 
training for 6 
months and 
followed by 
a 6 month 
home 
program 
 
Hojan et 
al.7 
(2017) 
RCT 72 >18yrs  -Men with high or 
intermediate risk prostate 
cancer that have scheduled 
androgen derived therapy 
for 36 months  
-Prior to radiation therapy  
-Good general condition 
-A minimum age 18 years 
old  
 
-Distant metastasis or 
disease progression that 
resulted in the patient 
receiving radiation 
therapy or the 
introduction of 
chemotherapy  
-Uncontrolled HTN or 
cardiac diseases resulting 
in circulation failure 
-Uncontrolled asthma  
-Insufficiently controlled 
metabolic disease, 
endocrine, rheumatic and 
absorption disorders as 
well as other tumors 
-Preexisting bone 
metastasis at high for 
fracture 
-Psychiatric illness or 
dementia or organic brain 
disease  
 
6  
-12 month 
aerobic and 
resistance 
exercise 
program 
 
Bourke et 
al.5 
(2013) 
  
RCT 100 53-
87yrs 
-Sedentary men with 
locally advanced or 
metastatic prostate cancer 
on long term ADT that had 
been receiving the therapy 
6 months prior to the 
recruitment for the study  
 
-Unstable angina, 
uncontrolled 
hypertension, recurrent 
myocardial infarction, 
pacemakers or painful and 
unstable bone metastasis 
32  -12 week 
lifestyle 
intervention 
consisting of 
aerobic and 
resistance 
exercise 
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OUTCOME MEASURED  
The outcome measured in all three RCT’s was the effect aerobic and resistance exercise 
had on fatigue in men with prostate cancer undergoing ADT and/or RT. The Hojan et al. and 
Bourke et al. studies both used The Functional Assessment of Cancer Therapy-Fatigue Scale and 
the Taaffe et al. study used The European Organization for Research and Treatment of Cancer 
Quality of life Questionnaire Core 36 to assess fatigue in the participants.3,5,7 The Taaffe et al. 
study assessed participants at baseline, 6 months, and 12 months.3 The Hojan et al. study 
collected data at baseline, 8 weeks into the program, and at 12 months.7 The Bourke et al. study 
conducted their assessments at baseline, 12 weeks and 6 months.5 
RESULTS 
All three studies analyzed in this systematic review are RCTs studying the effect of 
exercise on fatigue in men with prostate cancer undergoing ADT and or radiation therapy. 
Inclusion and exclusion criteria differed among the studies as well as the specific exercise 
intervention the participants received. All three studies contained continuous data that could not 
be converted into dichotomous data. Among the studies, changes in p value, ANOVA and f-
score were analyzed. 
 The Taaffe et al. study is a three-armed RCT with 163 participants.3 Participants were 
randomly assigned by computer to the follow three groups: ILRT (n=57), ART (n=54), and to 
DEL (n=48).3 A total of 7 participants had missing data for fatigue leaving a total of 156 men 
representing in the final analysis for the study.3 The author of the study states that compliance 
during the supervised exercise sessions were, “65% and 69% for ILRT at 6 mo and 12 mo, 
respectively, 69% for ART for the 1st 6-mo period, and 63% for DEL for the 6–12 mo period.”3 
During the study, no adverse events from the exercise interventions led to the withdraw of any 
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participants.3 All participants included in the study were men diagnosed with prostate cancer and 
scheduled to receive ADT for the next 12 months.3 During the trial 31 men in ART, 29 in DEL 
and 34 men in ILRT also received radiation therapy in combination with ADT.3 Men with an 
inability to exercise were excluded from the study and participants had to obtain medical 
clearance from their physician.3 Fatigue was assessed using the EORTC QLQ-C36 with higher 
scores indicating greater levels of fatigue reported by the participant.3 Each participants EORTC 
QLQ-C36 score report was not provided in this study however the overall mean score, standard 
deviation and p values were provided (table 2). At baseline, significant differences in level of 
fatigue was not seen among groups.3 The ILRT group saw a fatigue score reduction of 5.7 points 
from baseline by the 6 month assessment.3 Further reduction was not recorded by the 12 month 
mark.3 The ART group saw a 5.7 point reduction in fatigue by the 12 month mark.3 The DEL 
group had a very slight decrease in the fatigue score by the 6 month mark but reported a 5.5 point 
reduction in fatigue by the 12 month mark.3 A statically significant reduction in fatigue was seen 
for all three groups with reported p values <0.05.3  
Table 2. EORTC QLQ-C36 mean score at baseline, 6 months and 12 months; p value; mean(SD)  
Fatigue  Baseline 6 months 12 months p value 
ILRT 27.9 (20.7) 22.2 (15.4) 22.5 (16.6) 0.0005 
ART 23.4 (18.1) 21.9 (18.4) 17.7 (15.0) 0.0005 
DEL 25.8 (20.2) 24.6 (17.7) 20.3 (15.3) 0.022 
 
The Hojan et al. study is a 2-arm RCT with 72 participants randomly allocated to an 
exercise group (n=36) and a usual care group (n=36).7 During the study, 5 withdrew from the 
control group and 1 in the exercise group leaving 66 participants represented in the final data in 
the study.7 Participant compliance with the weekly supervised exercise sessions was 86% in the 
exercise group.7 The author of the study states that no side effects were noted from participants 
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during the study, however 3 overuse injuries occurred in the exercise group that did not lead to 
any withdraws.7 All participants in the study were men greater then 18 years old diagnosed with 
prostate cancer undergoing ADT and RT.7 Specific inclusion and exclusion criteria are listed in 
table 1.7 The FACT-F scale was used to measure the level of fatigue in participants and higher 
scores are indicative of less fatigue.7 The analysis of variance (ANOVA) was used to determine 
the difference in means among the two groups with regards to fatigue.7 Participants FACT-F 
score reports was not provided in this study but the mean score, standard deviation, f value and p 
value were provided (table 3). The author of the study states that, “ANOVA with repeated 
measures revealed significant differences between the 3 measurements with regard to all 
variables in the FACT-F questionnaire.” 7 A large drop in the FACT-F score was seen in the 
control group between assessments 1 and 2 while a slight increase was seen between the same 
assessments in the exercise group.7 During assessments 2 and 3 the FACT-F score in the exercise 
group was significantly higher than the control group indicating less fatigue.7 The calculated p 
value <0.0001 indicates the reduction in fatigue is statistically significant (table 3).7 
Table 3. FACT-F mean score (SD) reported at assessment 1-3 with reported f and p-value 
Parameters Assessment 1 
(baseline) 
Assessment 2  
(8 weeks) 
Assessment 3  
(10 months) 
F p-value 
 Exercise 
group 
Control 
group 
Exercise 
group  
Control 
group 
Exercise 
Group  
Control 
group 
 
FACT-F  
Score  
113.4 
(3.5) 
112.9 
(3.9) 
117.9 
(9.7) 
81.5 
(9.7) 
105.8 
(7.7) 
75.54 
(8.1) 
(2.111) 
=159.75 
<0.001 
 
The Bourke et al. study is a two-armed single blinded RCT with 100 participants 
randomly allocated to a lifestyle program group (n=50) or a usual care group (n=50).5 During the 
trial 15 participants withdrew from the intervention group and 17 from the usual care group 
leaving a total of 68 participants represented in the data in the study.5 Participant compliance was 
94% for the supervised exercise and 82% for the non-supervised exercise during the 12 week 
  
 
Metz, Exercise and Prostate Cancer 9 
study.5 The author of the study states there were no skeletal related adverse events that occurred 
during the study, but one man in the intervention group developed atrial fibrillation leading to 
withdraw and one death in the usual care group.5  All participants in the study were sedentary 
men diagnosed with prostate cancer receiving ADT for a minimum of 6 months prior to the study 
and plans of long term ADT.5 Specific inclusion and exclusion criteria for the study are listed in 
table 1.5 The FACT-F questionnaire was used to measure the level of fatigue in participants with 
higher score indicating less fatigue.5 Participants individual FACT-F score reports were not 
provided in this study but the mean FACT-F score, mean difference, confidence interval and p-
value were provided (table 4). The adjusted mean difference for the FACT-F score between the 
two groups at the 12 week assessment was 5.3 and 3.9 at the 6 month follow up.5 The author 
states that significant clinically relevant improvements in fatigue were seen at the 12 week mark 
among the two groups.5 Following the withdraw of supervision at the 6 month assessment these 
clinically relevant improvements were still present.5 The data in the study was determined to be 
statistically significant with reported p values of < 0.05 and a 95% confidence interval for both 
the 12 week and 6 month assessments (table 4).5  
Table 4. FACT-F mean score, mean difference, CI and p value for baseline, 12-week and 6 
month assessments 
 Control Intervention  Adjusted analysis 
 Mean  Mean Mean difference (95% CI) p 
Baseline FACT-
F  
41.4  40.3   
12 week FACT-
F  
42.4  45.8 5.3 (2.7-7.9) <0.001 
6 month FACT-
F  
41.9 43.6 3.9 (1.1-6.8) 0.0007 
 
DISCUSSION 
The three RCT’S discussed in this systematic review suggest that exercise can be utilized 
to mitigate fatigue experienced by men with prostate cancer undergoing treatment. The three 
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arms in the Taaffe et al. study had a decrease in the level of fatigue experienced by the 
participants.3 The DEL group in this study participated in an exercise program only during the 
last 6 months of the trial.3 A larger decrease was seen in the DEL group during these last 6 
months.3 The addition of the exercise program in the DEL group provided even further support 
that exercise can lead to a reduction in fatigue. The ART group interestingly continued to see a 
decrease in the level of fatigue at the 12-month assessment.3 Participants were instructed to 
perform a home-based exercise program for this 6-month duration.3 Therefore, participants 
continued to see a reduction in fatigue even when the exercise regimen was not supervised.  
The Hojan et al. study data also saw a similar reduction of fatigue in the exercise group.7 
Differing from the Taaffe et al. study, participants in the control group were instructed not to 
start any formal physical activity.7 All participants at baseline were undergoing ADT and 1 week 
away from starting RT treatment.7 During assessment 2, all participants were 1 week post RT.7 
As seen in table 3 the level of fatigue decreased in the exercise group and increased in the control 
group.7 Even with the addition of radiation therapy, a decline in fatigue was still seen in the 
experimental group and maintained during the final assessment.  
The Bourke et al. study focused on sedentary men diagnosed with prostate cancer and 
treated with ADT.5 During the 12-week assessment the level of fatigue reported by participants 
in the intervention group was lower than the levels reported by the control group.5 After the 
withdrawal of supervision the fatigue levels increased from the 12-week assessment but still 
decreased from the baseline assessment.5 Similar to the Taaffe et al. study, participants were still 
able to maintain a continual reduction in their fatigue level after withdrawing supervision.  
There were some limitations to the studies due to the lack of a sufficient population size. 
All studies included a sample size less then 160 after withdraws which is not a sufficient 
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population size to be comparable to the general population. The Taaffe et al. study noted that a 
possible confounding factor was that the participants in the trial were generally healthy and non-
smokers.3 Other limiting factors in the trial were that the exercise sessions allowed interactions 
and sharing of information amongst participants and that the men were in the first year of ADT 
so the results may not be comparable to longer durations of therapy.3 The Hojan et al. study 
noted the confounding factors in their trial to be an absence of a comparable control group.7 The 
Bourke et al. study noted there was improved exercise behavior in the control group that could 
have contributed to the reduced difference between the experimental group at the 6-month 
assessment.5 Double blind studies were not conducted in any of the three trials that could have 
led to researcher bias. Limitations present in this systematic review are due to differences in type 
of treatment, specific regimens, and length of treatment compared in the three studies. All three 
studies focused on ADT as a treatment modality; however, the Taaffe et al. study and the Hojan 
et at. study included men undergoing RT. Exercise regimens and length of treatment discussed in 
detail in the methods section differed among the studies as well.  
CONCLUSION 
Based on these three studies, aerobic and resistance exercise in men diagnosed with prostate 
cancer undergoing ADT and/or radiation therapy reduced the level of reported fatigue. Exercise 
is a cost-effective therapy for patients and can provide many other health benefits such as 
improving cardiorespiratory fitness. Medical providers can thus utilize exercise as a valuable tool 
in clinical practice. All three clinical trials were conducted on men undergoing only ADT and or 
radiation therapy. Future studies can investigate the effects that exercise has on fatigue in men 
receiving other common treatment modalities such as chemotherapy. Future studies can also 
include a larger population size and longer treatment trials.
 REFRENCES   
1. Key Statistics for Prostate Cancer | Prostate Cancer Facts. 
https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed 
October 1, 2018. 
 
2. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 
2011;108(6):806-813. doi:10.1111/j.1464-410X.2011.10365.x 
 
3. Taaffe DR, Newton RU, Spry N, et al. Effects of different exercise modalities on fatigue 
in prostate cancer patients undergoing androgen deprivation therapy. A year-long 
randomized controlled trial. European Urology. 2017;72(2):293-299. 
doi:10.1016/j.eururo.2017.02.019 
4. Papadakis M, McPhee S. Current Medical Diagnosis & Treatment 2018.57th ed. 
McGraw-Hill Education; 2018. 
5. Bourke L, Gilbert S, Hooper R, et al. Lifestyle changes for improving disease-specific 
quality of life in sedentary men on long-term androgen-deprivation therapy for advanced 
prostate cancer: A randomized controlled trial. European Urology. 2014;65(5):865-872. 
doi:10.1016/j.eururo.2013.09.040 
6. Hormone Therapy for Prostate Cancer. https://www.cancer.org/cancer/prostate-
cancer/treating/hormone-therapy.html. Accessed December 11, 2018. 
7. Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammation, 
cardiometabolic markers, and functional changes in men with prostate cancer. A 
randomized controlled trial of a 12-month exercise program. Polish Archives of Internal 
Medicine. 2017;127(1):25-35. doi:10.20452/pamw.3888 
 
 
 
 
